In the 2022 annual report, Guang Dong Wedge Co., LTD. disclosed that the company achieved operating revenue of RMB 794 million yuan (USD $115 million), with an increase of 20.97% year-on-year. It’s worth of notice that the company’s product “Golden Bifid”, the live combined bifidobacterium and lactobacillus tablets, attained a gross margin of up to 88.87%, and “Ding Jun Sheng”, the live lactobacillus capsule for vaginal use, attained a gross margin up to 91.41%. In addition, Wedge’s subsidiary company has cooperated with IFF in the United States to create a new profit growth point for the company with a series of micro-ecological health products. (Source: cj.sina)
Visit HPA-China’s Information Hub, CLICK HERE